CRISPR Therapeutics AG (CRSP) Net Income towards Common Stockholders (2015 - 2026)

CRISPR Therapeutics AG has reported Net Income towards Common Stockholders for 12 years, with the latest figure at -$122.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 9.6% year-over-year to -$122.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$600.2 million (down 3391.11% YoY) and the FY2025 annual result came in at -$613.2 million, down 1728.93% from the prior year.
• Net Income towards Common Stockholders advanced to -$122.9 million in Q1 2026 per CRSP's latest filing, from -$162.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $366.6 million in Q4 2024 and troughed at -$208.5 million in Q2 2025.
• A 5-year average of -$88.4 million and a median of -$116.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 310.09% in 2024, then tumbled 144.26% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$110.6 million in 2022, then surged by 180.84% to $89.4 million in 2023, then soared by 310.09% to $366.6 million in 2024, then slumped by 144.26% to -$162.2 million in 2025, then rose by 24.23% to -$122.9 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$122.9 million, -$162.2 million, and -$106.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.